

Sheet 1 of 2

#5


Substitute Disclosure Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 00537-182002	Application No. 09/744,846
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Societe De Conseils de Recherches et D'Applications Scientifiques SAS			
		Filing Date January 30, 2001	Group Art Unit		

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
MW	AA	4,853,371 A	August 1, 1989	Coy et al.			
MW	AB	5,506,339	4/9/96	Coy et al.	530	311	
MW	AC	5,688,530	11/18/97	Bodmer et al.	424	501	

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes      No
MW	AD	WO 98/08529	3/5/98	PCT			
MW	AE	WO 98/10786	3/19/98	PCT			
MW	AF	WO 98/51332	11/19/98	PCT			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MW	AG	Anthony et al., "Case Report: Lanreotide in the Management of Hypercalcemia of Malignancy," <u>American Journal of the Medical Sciences</u> , Vol. 309, No. 6, June 1995, pp. 312-314
	AH	Bartlett et al., "Reversal of tumor-associated hyperglucagonemia ....", <u>Surgery (ST. Louis)</u> , vol. 118, no. 1, July 1995, pp. 87-97
	AI	Chanson, "Traitements medicamenteux des adenomas hypophysaires", <u>Revue Du Practicien</u> , vol.46, June 15, 1996, pp. 1509-1513
	AJ	Hasler et al., "Role of The Pylorus in the Prevention of .....", <u>Gastroenterology</u> , vol. 100, no. 5, May 2, 1991, pp.A448
	AK	Hoeldtke et al., "Treatment of orthostatic hypotension with midodrine and octreotide", <u>J. Endocrin. &amp; Metab.</u> , Vol. 83, no. 2, February 1998, pp.339-343
	AL	Jaffrain-rea et al., "Visual improvement during octreotide therapy in a case of episellar meningioma", <u>Clinical Neurology and Neurosurgery</u> , vol. 100, no. 1, March 1998, pp. 40-43
	AM	Kang et al., "Visualization of Paget's disease during somatostatin receptor scintigraphy", <u>Clinical Nuclear Medicine</u> , vol. 24, no. 11, November 1999, pp.900-902
	AN	Kirk et al., "Somatostatin analogue in short term management of hyperinsulinism", <u>Archives of Disease in Childhood</u> , Vol. 63, No. 12, 1988, pp. 1493-1494
	AO	Khoo et al., "Palliation of malignant intestinal obstruction using octreotide," <u>European Journal of Cancer</u> , Vol. 30A, No. 1, 1994, pp. 28-30
	AP	Lamrani et al., "Effects of lanreotide, a somatostatin ... secretions in humans," <u>British Journal of Clinical Pharmacology</u> , Vol. 43, No. 1, 1997, pp. 65-70
	AQ	Mosdell et al., "Emerging indications for octreotide therapy, part 1," <u>Am. J. Hosp. Pharm.</u> , Vol. 51, No. 9, 1994, pp. 1184-1192
MW	AR	Mottet, et al., "Hemodynamic Effects of the Somatostatin Analog...Echo-Doppler Study," <u>Hepatology</u> , Vol. 27, No. 4, 1998, pp. 920-925

Examiner Signature	Date Considered
	03/02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 2 of 2

MAR 08 2002  
TECH CENTER 1600/2900


RECEIVED

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00537-182002	Application No. 09/744,846
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Societe De Conseils de Recherches et D'Applications Scientifiques SAS		
		Filing Date January 30, 2001	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>MM</i>	AS	Ono et al., "Effects of Octreotide Acetate Treatment for Scleroderma Bowel," <u>Kawasaki Medical Journal</u> , Vol. 22, No. 4, 1996, pp. 233-237
<i>V</i>	AT	Pavlovic et al., "Regression of Sclerodermatous Skin Lesions in a Patient with Carcinoid Syndrome Treated by Octreotide," <u>Archives of Dermatology</u> , Vol. 131, No. 10, 1995, pp. 1207-1209
	AU	Rieu et al., "Paradoxical effect of somatostatin analogues on the ectopic secretion .....", <u>Hormone Research</u> , vol. 39, no. 5-6, November 1993, pp.207-212
	AV	Sobhani et al., "Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers," <u>British Journal of Clinical Pharmacology</u> , Vol. 41, No. 2, 1996, pp. 109-114
	AW	Srkalovic et al., "Evaluation of Receptors for Somatostatin in various tumors using different analogs", <u>J. Endocrine. &amp; Metab.</u> , vol. 70, no. 3, March 1992, pp. 661-669
	AX	Weckbecker et al., "Somatostatin Analogs for Diagnosis and Treatment of Cancer," <u>Pharmacology and Therapeutics</u> , Vol. 60, No. 2, 1994, pp. 245-264
	AY	Woltering et al., "Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection," <u>Surgery</u> , Vol. 116, No. 6, 1994, pp. 1139-1147
<i>MW</i>	AZ	Zeilke et al., "Octreotide: Effective treatment for hyperparathyroidism?.....", <u>Surgery (St. Louis)</u> , vol. 121, no. 6, June 1997, pp. 606-610

Examiner Signature 	Date Considered <i>03/02</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION  
(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
00537-182002APPLICATION NO.  
09/744,846APPLICANT  
Jacques-Pierre MoreauFILING DATE  
May 24, 2001GROUP  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
MJ	AA	5,073,541	12/17/91	Taylor et al.	514	9	
	AB	5,147,856	09/15/92	Ramwell et al.	514	16	
	AC	5,411,943	05/02/95	Bogden	514	16	
	AD	5,504,069	04/02/96	Bogden et al.	514	11	
MJ	AE	5,686,418	11/11/97	Culler	514	17	
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
MJ	AL	0 469 520 A2	29.07.91	EPO			
	AM	0 469 520 A3	29.07.91	EPO			
	AN	0 469 520 B1	29.07.91	EPO			
	AO	WO 98/08528	05.03.98	PCT			
MJ	AP	HU P9102452 A	07.22.91	Hungry			
MJ	AQ						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MJ	AR	Abelson, James L., et al.; "Treatment of Panic-Like Attacks with a long-Acting Analogue of Somatostatin"; 1990; J. Clin Psychopharmacol; Vol. 10; Pages 128-132
	AS	Alhindawi, Ritha, et al.,; "Severe Secretory Diarrhea With Elevated Gastrin-Releasing Peptide Controlled by Somatostatin Analogue: a Case Report"; 1990; Canada J. Surg.; Vol. 33:2; Pages 139-142
MJ	AT	Ambrosi, Bruno; "Precocious puberty in a boy with a PRL-, and FSH-secreting pituitary tumour: Hormonal and immunocytochemical studies"; 1990; Acta Endocrinological; Vol. 122; Pages 569-576

EXAMINER

DATE CONSIDERED

INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION

(Use several sheets if necessary)



ATTORNEY DOCKET NO. 00537-182002	APPLICATION NO. 09/744,846
APPLICANT Jacques-Pierre Moreau	
FILING DATE May 24, 2001	GROUP 1615

RECEIVED  
APR 15 2002  
TECH CENTER 1600  
1600 1600 1600

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE 1600 1600 APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES      NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MM	AU	Arrigoni, Arrigo, et al.; "Octreotide Treatment of Bleeding Small Intestine Amiodysplasia"; 1992; Amer. Journal Gastroenterol; Vol. 87; Page 1311; Abs. 275
	AV	Bartlett, David L., et al.; "Glucose Metabolism and Hormone Treatment in Cancer Cachexia"; 1991; Surgical Forum (Amer. Coll. Surg.), Vol 42; Pages 14-16
	AW	Bauer, W.; "Octreotide: drug development of a Constrained Somatostatin Analogue" 1990; Europe J. Pharmacol; Vol. 183; Page 55
	AX	Bianco, James A., et al.; "The Somatostatin Analog Octreotide in the Management of the Secretory Diarrhea of the Acute Intestinal Graft-Versus-Host Disease in a Patient After Bone Marrow Transplantation"; 1990; Vol. 49:6; Pages 1194-1195
	AY	Branch, M.S., et al.; "Somatostatin Analogue (Octreotide) Inhibits Lower Esophageal Sphincter Relaxation"; 1991; Gastroenterol, Vol. 100 No. 5, Part 2; Page A425
	AZ	Camisa, Charles, et al.; "Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin); 1990; Cleveland Clinic J. Medicine,; vol. 57:1; Pages 71-76
	BA	Cello, J.P., et al.; "Controlled Clinical Trial of Octreotide for Refractory AIDS-Associated Diarrhea; 1990; Vol. 98:5 Part 2; Page A163
	BB	Chang, T.C., et al.; "Octreotide and Graves' ophthalmopathy and pretibial myxoedema"; 1992; Brit Med Journ; Vol. 304; Page 158
MM	BC	Christensen, Claus; "The Somatostatin Analogue SMS 201-995 In Long-Term treatment of Vipoma"; 1989; Acta Chir Scand,; Vol 155; Pages 541-543

EXAMINER


DATE CONSIDERED

08/02

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
00537-182002APPLICATION NO.  
09/744,846APPLICANT  
Jacques-Pierre MoreauFILING DATE  
May 24, 2001GROUP  
1615

RECEIVED  
TECH CENTER 1600  
APR 15 2002  
1600/2000

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MPS	BD	Clark, R.V., et al; "Control of Cushing's Syndrome Secondary to Ectopic Acth With Octreotide"; 1990; Clin, Res; Vol 38:4; Page 943A
	BE	Fedorak, Richard N., et al.; "Absence of effect of somatostatin analogue (SMS 201-995) in diarrhea associated with inflammatory bowel disease; 1989; Canada J. Gastroenter; Vol. 3:2; Pages 53-57
	BF	Hartley, J.E., et al.; "Ruptured pancreatic pseudocyst"; 1992; Journal Royal Soc. Med.; Vol. 85; Pages 107-108
	BG	Hoeldtke, Robert D., et al.; "Treatment of Orthostatic Hypotension: Interaction of Pressor Drugs and Tilt Table Conditioning; 1988; Arch Phys Med Rehabil; Vol 69; Pages 895-898
	BH	Jenkins, S.A., et al.; "Management of massive upper gastrointestinal haemorrhage from multiple sites of peptic ulceration with somatostatin and octreotide - a report of five cases"; 1992; Gut, Vol. 33; Pages 404-407
	BI	Koberstein, B., et al.; "Paralytischer Ileus als Erstmanifestation eines malignen VIPoms des Pankreas - Fallbeschreibung mit Literaturubersicht" 1990; Z Gastroenterol; Vol. 28 Pages 295-301
	BJ	Kooner, J.S., et al.; "Haemodynamic responses to food ingestion in normal human subjects before and after the somatostatin analogue, octreotide (SMS 201-995)"; 1989; Proceeding of the Brit J. Clin Pharm. Vol. 28; Pages 735P-736P
	BK	Koper, J.W., et al.; "Somatostatin Inhibits the Activity of Adenylate Cyclase in Cultured Human Meningioma Cells and Stimulates their Growth"; 1992; Journal of Clinical Endo. And Metabolism; Vol. 74:3; Pages 543-547
MPS	BL	Laron, Z., et al; "Somatostatin Analogues in the Management of Benign Insulinomas"; 1990; Israel Journal of Medical Sciences; Vol 26; Pages 1-2


EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
00537-182002APPLICATION NO.  
09/744,846APPLICANT  
Jacques-Pierre MoreauFILING DATE  
May 24, 2001GROUP  
1615

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES      NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	BM	Micic, D., et al.; "The Effect of the Long Acting Somatostatin Analogue (SMS 201-995)" in the Treatment of Beta Cell Tumors of the Pancreas"; 1990; Digestion; Vol. 16: Suppl 1; Page 70; Abs. 193
"	BN	Miller, David; et al.; "Hypercalcemia due to hyperparathyroidism treated with a somatostatin analogue"; 1991; Canada J. Surg. Vol. 33:2; Pages 139-142
"	BO	Modigliani, E., et al.; "Effets de l'administration sous cutanee de la sandostatine (SMS 201.995) en sous cutane dans 18 cas de cancer medullaire du corps thyroide"; 1989; Annales d'Endocrinologie; Vol. 50; pages 483-488
"	BP	Mozell, Everett et al.; "Effect of Somatostatin Analog on Peptide Release and Tumor Growth in the Zollinger-Ellison"; 1990; Gynecology & Obstetrics; Vol. 170; Pages 476-484
"	BQ	Nott, D.M. et al.; "Effects of Sandostatin in ameliorating the complications of small bowel obstruction in rats"; 1990; British J. Surg; Vol. 77; Pages 691-713
"	BR	O'Donnell, L.J.D., et al.; "Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome"; 1990; Aliment Pharmacol. Therap; Vol. 4; Pages 177-182
"	BS	Palmieri, G.M.A., et al.; "Octreotide, A Somatostatin Analog, simultaneously Diminished Bone Resorption and Enhanced Formation, in a Patent with Severe Paget's Disease"; 1992; J. Bone & Mineral Research; Vol. 7:1; Abs. 591; Page S240
"	BT	Petrelli, N., et al; "Tolerance and Response of Somatostatin Analogue (SMS) Sandostatin® for the Treatment of Chemotherapy Induced Diarrhea"; 1991; Proc. Amer. Soc. Clin Oncol; Vol. 10, Abs 417; Page 138
PM	BU	Prelevic, Gordana M. et al.; " Effects of the Somatostatin Analogue, Octreotide, in Polycystic Ovary Syndrome"; 1992; Metabolism; Vol. 41:9, suppl. 2; Pages 76-79


EXAMINER

DATE CONSIDERED

RECEIVED  
APR 15 2002  
TECH CENTER 1600/2300

INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION

(Use several sheets if necessary)



APPLICATION NO.

GROUP

RECEIVED  
TECH CENTER 1600/2900  
APR 15 2002

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MR	BV	Soudah, H., et al.; "Somatostatin Analog Stimulates Intestinal Migrating Motor Complex Activity in Normal Volunteers and Patients with Progressive Systemic Sclerosis"; 1990; Gastroenterology, Vol. 98:5, Part 2 Suppl; Page A129
	BW	Soudah, H., et al.; "Somatostatin Analog Stimulates Intestinal Migrating Motor Complex Activity and Reduces Bacterial Over Growth in Patients with Progressive Systemic Sclerosis"; 1991; Clinical Research; Vol. 39:2; Page 303A
	BX	Tulassay, Z.; "Long-Acting Somatostatin Analogue in the Prevention of the pancreatitis-Like Changes Following ERCP" 1990; Gastroenterology; Vol. 98:5 Part 2; Page A238
MR	BY	Wilson, D., et al.; "Long-Term Treatment of Hypoglycaemia Due to Nesidioblastosis Using Somatostatin Analogue SMS 201-995"; 1989; Irish J. of Med. Sci; Vol 158:1 Pages 31-32
	BZ	
	CA	
	CB	
	CC	
	CD	

EXAMINER

DATE CONSIDERED